Trial reportScience translational medicine2023
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana.
Registry-linked trialOpen access · greenAbstract readClinical Trial
In one paragraph
Trial report in Science translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03707977 (A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana), which is not on this map. Cited by 38 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Broadly neutralizing antibodies for HIV therapy in clinical trials: a systematic review.Infectious diseases of poverty · 2026Pooled it
- VRC01 with antiretroviral initiation in infants is well tolerated, and higher concentrations associate with greater HIV-1 DNA declines.Science translational medicine · 2026Trial
- ART-free HIV-1 remission in children with in-utero HIV-1 after very early ART (IMPAACT P1115): a multicentre, open-label, phase 1/2 proof-of-concept study.The lancet. HIV · 2025Trial
- Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies: a qualitative approach.HIV research & clinical practice · 2026Article
- Could AAV-vectored delivery of broadly neutralizing antibodies (bNAbs) reduce virologic failure in children diagnosed with perinatal HIV?Human vaccines & immunotherapeutics · 2026Review
- Article
- Human monoclonal antibodies targeting α-Gal restrict IgE engagement of α-Gal syndrome allergens.The Journal of clinical investigation · 2026Article
- Vaccine elicitation of HIV broadly neutralizing antibodies from genome-edited B cells in non-human primates and derived lymphoid organoids.Gene therapy · 2026Article
- Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies.Communications medicine · 2026Review
- The Importance of Pediatric Nonhuman Primate Models in Translational HIV Research.Journal of medical primatology · 2026Review
- CROI 2026: Antiretroviral THerapy in Adult, Maternal, and Pediatric Populations With HIV.Topics in antiviral medicine · 2026Review
- Delayed viral rebound post-ART interruption in infant macaques given SIV-specific neutralizing antibodies.Cell reports. Medicine · 2026Article
- Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Immune correlates of HIV-1 rebound during broadly neutralizing antibody treatment in young children.The Journal of clinical investigation · 2026Article
- Review
- Broadly neutralizing antibodies for treatment of HIV in children in the Global South: rationale and challenges.Frontiers in pediatrics · 2026Review
- Heavy-chain immunoglobulin locus editing in rhesus macaque B cells to confer antibody production.Molecular therapy. Methods & clinical development · 2025Article
- Identifying correlates of viral rebound timing and viral control in SHIV-infected infant macaques after ART interruption.Science translational medicine · 2025Article
- Article
- A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV.Structure (London, England : 1993) · 2025Article
Corrections and comments
- Commented on by
Authors and funding
32 authors at 11 institutions in 2 countries.
Roger L ShapiroDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0002-4832-6275
Gbolahan AjibolaBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0002-5408-4823
Kenneth MaswabiBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0002-7944-4637
Michael HughesDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Bryan S NelsonDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0002-4964-067X
Aischa NiesarRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0009-0007-7082-3191
Molly Pretorius HolmeDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Kathleen M PowisDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0002-4478-4471
Maureen SakoiBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0009-0008-5222-7756
Oganne BatlangBotswana Harvard Health Partnership, Gaborone, Botswana.
Sikhulile MoyoDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0003-3821-4592
Terence MohammedBotswana Harvard Health Partnership, Gaborone, Botswana.
Comfort MaphorisaBotswana Harvard Health Partnership, Gaborone, Botswana.ORCID 0000-0003-2528-7469
Kara BennettBennett Statistical Consulting Inc., Ballston Lake, NY 12019, USA.ORCID 0000-0002-9465-8983
Zixin HuDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Francoise GiguelDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Jacqueline D ReevesLabcorp-Monogram Biosciences Inc., South San Francisco, CA 94080, USA.
Michael A ReevesLabcorp-Monogram Biosciences Inc., South San Francisco, CA 94080, USA.
Ce GaoRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-3775-790X
Xu YuRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0002-8295-884X
Margaret E AckermanThayer School of Engineering, Dartmouth College, Hanover, NH 03755, USA.ORCID 0000-0002-4253-3476
Adrian McDermottVaccine Research Center, Bethesda, MD 20892, USA.ORCID 0000-0003-0616-9117
Marlene CooperFrontier Science & Technology Research Foundation Inc., Amherst, NY 14226, USA.ORCID 0009-0001-1623-4229
Marina CaskeyRockefeller University, New York, NY 10065, USA.ORCID 0000-0003-1727-8693
Lucio GamaVaccine Research Center, Bethesda, MD 20892, USA.ORCID 0000-0001-9511-012X
Patrick Jean-PhilippeNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA.
Dwight E YinNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20892, USA.ORCID 0000-0002-8599-1004
Edmund V CapparelliDepartment of Pediatrics, University of California San Diego, La Jolla, CA 92037, USA.ORCID 0000-0002-1630-0505
Shahin LockmanDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.ORCID 0000-0002-5384-9716
Joseph MakhemaDepartment of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA.
Daniel R KuritzkesDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Mathias LichterfeldRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.ORCID 0000-0001-9865-8350
Harvard University · USBotswana Harvard AIDS Institute Partnership · BWBrigham and Women's Hospital · USRagon Institute of MGH, MIT and Harvard · USLabCorp (United States) · USNational Institutes of Health · USDartmouth College · USFrontier Science & Technology Research Foundation · USRockefeller University · USStatistical Research (United States) · USUniversity of California San Diego · US
Funding
Pediatric Adolescent Virus Elimination (PAVE) Martin Delaney CollaboratoryUM1AI164566 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Ann M Chahroudi, Deborah Persaud · 2021 to 2026
$35.5MA clinical trial to evaluate the impact of broadly neutralizing antibody VRC01 on HIV viral reservoir and maintenance of suppression in a cohort of early-treated children in BotswanaU01AI135940 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI KURITZKES, DANIEL R., LICHTERFELD, MATHIAS · 2018 to 2024
$10.4MMentoring in patient-oriented research to finding a cure for HIV-1 infectionK24AI155233 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI LICHTERFELD, MATHIAS · 2021 to 2025
$958kViral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682kFIC NIH HHS K43 TW012350NIAID NIH HHS K24 AI155233NIAID NIH HHS U01 AI135940NIAID NIH HHS UM1 AI164566
Abstract
Broadly neutralizing antibodies (bNAbs) may provide an alternative to standard antiretroviral treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects against HIV-1 reservoirs. We conducted a prospective clinical trial with two HIV-1 bNAbs (VRC01LS and 10-1074) in children (
Indexed as
HIV-1HIV InfectionsAntibodies, NeutralizingAnti-Retroviral AgentsBotswanaBroadly Neutralizing AntibodiesChildHIV AntibodiesHumansLeukocytes, MononuclearProspective StudiesViremiaAntibodies, NeutralizingAnti-Retroviral AgentsBroadly Neutralizing AntibodiesHIV Antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT03707977ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.